Exxonmobil Investment Management Inc. TX reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 13.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,232 shares of the company’s stock after selling 15,016 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Zoetis were worth $5,878,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Guardian Life Insurance Co. of America boosted its position in Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after buying an additional 13 shares in the last quarter. Sii Investments Inc. WI raised its position in Zoetis by 0.3% in the first quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock valued at $383,000 after buying an additional 23 shares during the last quarter. Argent Trust Co raised its position in Zoetis by 0.8% in the first quarter. Argent Trust Co now owns 4,132 shares of the company’s stock valued at $221,000 after buying an additional 32 shares during the last quarter. CENTRAL TRUST Co raised its position in Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock valued at $142,000 after buying an additional 49 shares during the last quarter. Finally, First Interstate Bank raised its position in Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock valued at $120,000 after buying an additional 76 shares during the last quarter. Institutional investors and hedge funds own 94.51% of the company’s stock.
Shares of Zoetis Inc. (ZTS) traded down 2.96% during mid-day trading on Tuesday, hitting $60.00. The stock had a trading volume of 4,663,668 shares. The stock’s 50-day moving average price is $62.59 and its 200-day moving average price is $57.66. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $63.85. The firm has a market cap of $29.45 billion, a PE ratio of 34.88 and a beta of 1.02.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. Zoetis’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.49 EPS. On average, analysts anticipate that Zoetis Inc. will post $2.33 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Thursday, June 15th will be issued a $0.105 dividend. This represents a $0.42 annualized dividend and a yield of 0.70%. The ex-dividend date is Tuesday, June 13th. Zoetis’s dividend payout ratio is currently 24.42%.
ILLEGAL ACTIVITY WARNING: This report was published by BBNS and is owned by of BBNS. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://baseballnewssource.com/markets/zoetis-inc-zts-position-cut-by-exxonmobil-investment-management-inc-tx-updated-updated-updated/1196549.html.
ZTS has been the topic of a number of research analyst reports. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price target on the stock in a research report on Wednesday, May 10th. Jefferies Group LLC raised their price target on Zoetis from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. BMO Capital Markets reissued a “buy” rating and set a $60.00 price target on shares of Zoetis in a report on Thursday, May 4th. Argus reissued a “buy” rating and set a $69.00 price target (up from $60.00) on shares of Zoetis in a report on Tuesday, May 30th. Finally, CL King assumed coverage on Zoetis in a report on Friday, May 26th. They set a “buy” rating and a $71.00 price target for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the stock. Zoetis has an average rating of “Buy” and an average target price of $64.78.
In related news, insider Catherine A. Knupp sold 5,785 shares of the company’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $60.16, for a total value of $348,025.60. Following the completion of the transaction, the insider now owns 24,415 shares of the company’s stock, valued at approximately $1,468,806.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.31% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with our FREE daily email newsletter.